A Polymorphism in the HLA-G 3′-UTR Influences Targeting of mir-148 and is Associated with Asthma

Tan, Zheng; Fan, Junmei; Shon, A M; Schwartz, Matthew G.; Camoretti-Mercado, Blanca; Ober, Carole

doi:10.1016/j.jaci.2005.12.563

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Circulating miRNA concentrations are dysregulated in atopic conditions (20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35). For example, concentrations of miR-21 are elevated in the skin of patients with AD and in the bronchial cells of patients with asthma (20).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Infant consumption of microRNA miR-375 in human milk lipids is associated with protection from atopy

Hicks

Beheshti

Chandran

et al. 2022

The American Journal of Clinical Nutrition

View full text Add to dashboard Cite

Background Human milk is thought to reduce infant atopy risk. The biologic mechanism for this protective effect is not fully understood. Objectives We tested the hypothesis that infant consumption of four microRNAs (miR-146b-5p, miR-148b-3p, miR-21–5p, and miR-375–3p) in human milk would be associated with reduced atopy risk. Design The Breast Milk IMPACT Study involved a cohort of mother-infant dyads who planned to breastfeed beyond four months. Infant consumption of the four human milk microRNAs in the first six months was calculated as the product of milk microRNA concentration and the number of human milk feeds, across three lactation stages: early milk (0–4 weeks), transitional milk (4–16 weeks), and mature milk (16–24 weeks). The primary outcome was infant atopy in the first year, defined as atopic dermatitis, food allergies, or wheezing. The final analysis included 432 human milk samples and 7,824 weeks of longitudinal health data from 163 dyads. Results Seventy-three infants developed atopy. Forty-one were diagnosed with atopic dermatitis (25%), 33 developed food allergy (20%), and 10 had wheezing (6%). Eleven developed > 1 condition (7%). Infants who did not develop atopy consumed higher levels of miR-375–3p (d = 0.18, P = 0.022, adj P = 0.044) and miR-148b-3p (d = 0.23, P = 0.007, adj P = 0.028). Consumption of miR-375–3p (X2 = 5.7, P = 0.017, OR = 0.92, 95% CI = 0.86, 0.99) was associated with reduced atopy risk. Levels of miR-375–3p increased throughout lactation (r = 0.46, F = 132.3, P = 8.4 × 10−34) and were inversely associated with maternal body mass (r = -0.11, t = -2.1, P = 0.032). Conclusions This study provides evidence that infant consumption of miR-375–3p may reduce atopy risk.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Increases in miR-146 are associated with reduced inflammation in airway smooth muscle, and protection from asthma and AD (22,27). Polymorphisms targeting miR-148 have also been implicated in asthma (28). Notably, all of these miRNAs have a robust presence in human milk (29).…”

Section: Introductionmentioning

confidence: 99%